Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CAR-T Meeting 2022 | Strategies to overcome the current obstacles in CAR-T manufacturing

Christian Buchholz, PhD, Paul-Ehrlich-Institut, Langen, Germany, comments on strategies to reduce the manufacturing time of chimeric antigen receptor T-cell (CAR-T) therapies, focusing on in vivo CAR-T generation. Currently, CAR-T manufacturing is a complex, costly and time-consuming process. Strategies to reduce the manufacturing time and make CAR-T therapy available to a larger number of patients include producing off-the-shelf allogeneic CAR-Ts, manufacturing CAR-Ts directly at the hospital, and developing new manufacturing platforms. Another approach is in vivo CAR-T generation, which consists in injecting a vector that delivers the CAR-T into the patient using a viral vector or lipid nanoparticles. So far, this promising off-the-shelf approach has been successful in humanized mice, but it is necessary to evaluate it in larger animal models. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.